Clinical bottom line
Emerging evidence suggests that dysfunction of the hypothalamic-pituitary-gonadal (HPG) axis may contribute to metabolic dysregulation in diabetes, particularly in men with type 2 diabetes and hypogonadism. Therapeutic strategies targeting HPG axis restoration, including testosterone replacement and modulation of gonadotropin-releasing hormone (GnRH) signaling, are under investigation for their potential to improve insulin sensitivity, glycemic control, and associated metabolic outcomes. However, current clinical data remain limited, and the role of HPG axis–targeted therapies in routine diabetes management warrants cautious interpretation pending further validation.
What the evidence shows
The HPG axis orchestrates reproductive hormone secretion through a feedback loop involving hypothalamic GnRH, pituitary gonadotropins, and gonadal sex steroids (Fink et al., 1984). In diabetes, particularly type 2 diabetes, hypogonadism is common and may exacerbate insulin resistance and adiposity, suggesting a bidirectional relationship between metabolic and reproductive endocrine dysfunction (Caroppo et al., 2009). Observational studies have documented lower testosterone levels in men with type 2 diabetes, correlating with worse glycemic indices and increased cardiovascular risk.
Mechanistically, impaired HPG axis signaling may contribute to altered insulin signaling pathways and inflammatory processes implicated in diabetes pathophysiology (Ahmad Mir Hilal et al., 2019). Experimental models indicate that restoration of testosterone levels can improve insulin sensitivity and reduce adipose tissue inflammation, although translation to clinical outcomes remains under study.
Recent narrative reviews highlight the complexity of HPG axis dysfunction in aging and metabolic disease, emphasizing the need for individualized assessment of pituitary-gonadal function in diabetic patients, especially older men (Curtò et al., 2016). Moreover, stress and hypothalamic-pituitary-adrenal (HPA) axis activation may interact with HPG axis suppression, further complicating metabolic regulation (Mbiydzenyuy Ngala Elvis et al., 2024).
Clinical trials of testosterone replacement therapy (TRT) in hypogonadal men with type 2 diabetes have shown modest improvements in insulin resistance and body composition, but results are heterogeneous and limited by small sample sizes and short durations. The safety profile of TRT, particularly regarding cardiovascular events, remains a concern, underscoring the need for careful patient selection and monitoring.
Beyond TRT, novel approaches targeting upstream regulators of the HPG axis, such as GnRH analogs or modulators, are largely experimental but represent a putative avenue for modulating metabolic and reproductive endocrine axes concurrently.
Caveats and uncertainty
The causal relationship between HPG axis dysfunction and diabetes remains incompletely defined, with confounding factors such as obesity, aging, and comorbidities complicating interpretation. Most clinical evidence derives from observational or small interventional studies, limiting generalizability.
Testosterone replacement therapy carries potential risks, including erythrocytosis, prostate effects, and cardiovascular events, necessitating individualized risk-benefit assessment. Long-term safety data in diabetic populations are insufficient.
The heterogeneity of hypogonadism phenotypes in diabetes (primary vs secondary) and the influence of concurrent HPA axis dysregulation add complexity to therapeutic targeting. Additionally, female patients with diabetes and HPG axis alterations remain understudied.
Emerging therapies targeting GnRH or pituitary function are largely preclinical or early-phase clinical investigations, with unknown efficacy and safety profiles in diabetes.
How this may change practice
Clinicians managing patients with type 2 diabetes should maintain awareness of the potential interplay between metabolic and reproductive endocrine dysfunction, particularly in men presenting with symptoms suggestive of hypogonadism. Assessment of HPG axis function, including serum testosterone and gonadotropins, may be considered in selected patients with poor metabolic control or unexplained fatigue and sexual dysfunction.
While testosterone replacement therapy may be considered for hypogonadal men with diabetes, it should be approached cautiously, with adherence to current endocrinology guidelines and close monitoring for adverse effects.
Future advances in therapies modulating HPG axis signaling may offer novel adjunctive options for improving metabolic outcomes in diabetes, but these remain investigational. Multidisciplinary collaboration between endocrinologists, diabetologists, and reproductive specialists will be essential to optimize individualized care.